Key result
Kaiyujiangzhuo formula alleviates diet-induced glycolipid metabolic disorders in mice via PPARγ inhibition and arginine regulation.
Why the study?
Although Kaiyujiangzhuo formula has been used to treat glycolipid metabolic disorders, the potential molecular mechanism underlying its therapeutic effect remained unclear.
Does Kaiyujiangzhuo formula alleviate glycolipid metabolic disorders in a high-fructose and high-fat diet mouse model?
Does Kaiyujiangzhuo formula alleviate glycolipid metabolic disorders in a high-fructose and high-fat diet mouse model?
Kaiyujiangzhuo formula demonstrates therapeutic potential for glycolipid metabolic disorders by modulating ERK-mediated PPARγ-Ser273 phosphorylation and arginine metabolism in a preclinical model.
No immediate clinical implications from mouse data; leaves open translation of Kaiyujiangzhuo formula to human metabolic disorders.
ETHNOPHARMACOLOGICAL RELEVANCE: Kaiyujiangzhuo formula (KYJZ) is an optimized herbal formulation derived from the classical prescription "Dahuang Huanglian Xiexin decoction," recorded in the ancient Chinese monograph Shang Han Lun. For many years, KYJZ has been used to treat glycolipid metabolic disorders in China, particularly in Jilin, Changchun, and Beijing, with significant therapeutic efficacy. AIM OF THE STUDY: This study aimed to clarify the potential molecular mechanism underlying the therapeutic effect of KYJZ. MATERIALS AND METHODS: The chemical constituents of KYJZ and its absorbed components in the blood were identified using LC-MS/MS. A mouse model of glycolipid metabolic disorders was induced by feeding a high-fructose and high-fat diet (HFHFD) to evaluate the ameliorative effects of KYJZ. The mechanism of KYJZ was studied using multi-omics techniques, including transcriptomics, untargeted metabolomics, and 16S rRNA gene sequencing. RESULTS: We identified that compounds represented by neomangiferin, aloe-emodin, and ginsenoside Re may be the active constituents through which KYJZ exerts its therapeutic effects. Furthermore, we demonstrated the effectiveness of KYJZ in treating HFHFD-induced glycolipid metabolic disorders. Specifically, KYJZ reduced fasting blood glucose levels, alleviated insulin resistance, enhanced insulin sensitivity, and improved lipid profiles. Mechanistically, KYJZ reduced the hepatic activity of ERK1/2, which reduced PPARγ phosphorylation at Ser273. In addition, our comprehensive metabolomics and intestinal microbiota analysis revealed that KYJZ rectified the homeostatic imbalance of liver and intestinal arginine metabolism induced by an HFHFD. CONCLUSIONS: KYJZ exerted a beneficial effect against glycolipid metabolic disorders through a unique mechanism that inhibited hepatic PPARγ-Ser273 phosphorylation and regulated arginine metabolism homeostasis.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied Glycolipid metabolic disorders (mouse model). Kaiyujiangzhuo formula (KYJZ) vs. High-fructose and high-fat diet (HFHFD) control was evaluated on Glycolipid metabolic disorders (fasting blood glucose, insulin resistance, lipid profiles). Kaiyujiangzhuo formula alleviated high-fructose and high-fat diet-induced glycolipid metabolic disorders in mice by inhibiting hepatic PPARγ-Ser273 phosphorylation and regulating arginine metabolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: